Reported 2 days ago
The article explores AbbVie Inc. (NYSE:ABBV) as a strong contender among pharmaceutical stocks for long-term growth, highlighting its recent financial performance and successful product lines, especially its ex-Humira platform. As U.S. pharmaceutical companies increasingly seek partnerships with Chinese firms, industry dynamics are shifting, but AbbVie remains optimistic about its future, bolstered by promising drugs like Skyrizi and Rinvoq, alongside a recent dividend increase. The analysis positions AbbVie as the fourth-best pharma stock to own for sustainable growth.
Source: YAHOO